Skip to main content
. 2022 Oct 21;12(5):6182–6189. doi: 10.1002/cam4.5350

TABLE 2.

Base‐case analysis results

Strategies Cost Incr Cost LYs Incr LYs ICER/ LYs QALYs Incr QALYs ICER/ QALYs
Chemotherapy 13991.31 0.66 0.45
Pembrolizumab + Chemotherapy 178867.73 164876.42 1.71 1.04 159877.76 1.01 0.56 293513.17

Abbreviations: ICER, Incremental cost‐effectiveness ratio; Incr Cost, Incremental cost; Incr Lys, Incremental life‐years; Incr QALYs, Incremental Quality‐adjusted life‐years; Lys, life‐years; QALYs, Quality‐adjusted life‐years.